Now showing items 1-8 of 8

    • Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. 

      Bozkurt, MF; Virgolini, I; Balogova, S; Beheshti, M; Rubello, D; Decristoforo, C; Ambrosini, V; Kjaer, A; Delgado-Bolton, R; Kunikowska, J; Oyen, WJG; Chiti, A; Giammarile, F; Sundin, A; Fanti, S (2017-08)
      PURPOSE & METHODS: Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline ...
    • Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. 

      Went, M; Sud, A; Försti, A; Halvarsson, B-M; Weinhold, N; Kimber, S; van Duin, M; Thorleifsson, G; Holroyd, A; Johnson, DC; Li, N; Orlando, G; Law, PJ; Ali, M; Chen, B; Mitchell, JS; Gudbjartsson, DF; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Campo, C; Bandapalli, OR; Einsele, H; Gregory, WA; Gullberg, U; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Johnsson, E; Kristinsson, SY; Mellqvist, U-H; Nahi, H; Easton, D; Pharoah, P; Dunning, A; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; Nickel, J; Nöthen, MM; Rafnar, T; Ross, FM; da Silva Filho, MI; Thomsen, H; Turesson, I; Vangsted, A; Andersen, NF; Waage, A; Walker, BA; Wihlborg, A-K; Broyl, A; Davies, FE; Thorsteinsdottir, U; Langer, C; Hansson, M; Goldschmidt, H; Kaiser, M; Sonneveld, P; Stefansson, K; Morgan, GJ; Hemminki, K; Nilsson, B; Houlston, RS; PRACTICAL consortium (2018-09-13)
      Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous ...
    • Monitoring the ERSPC trial. 

      De Koning, HJ; Hakulinen, T; Moss, SM; Adolfsson, J; Smith, PH; Alexander, FE (2003-12)
    • Online dose reconstruction for tracked volumetric arc therapy: Real-time implementation and offline quality assurance for prostate SBRT. 

      Kamerling, CP; Fast, MF; Ziegenhein, P; Menten, MJ; Nill, S; Oelfke, U (2017-11)
      PURPOSE: Firstly, this study provides a real-time implementation of online dose reconstruction for tracked volumetric arc therapy (VMAT). Secondly, this study describes a novel offline quality assurance tool, based on ...
    • seXY: a tool for sex inference from genotype arrays. 

      Qian, DC; Busam, JA; Xiao, X; O'Mara, TA; Eeles, RA; Schumacher, FR; Phelan, CM; Amos, CI (2017-02-15)
      Motivation: Checking concordance between reported sex and genotype-inferred sex is a crucial quality control measure in genome-wide association studies (GWAS). However, limited insights exist regarding the true accuracy ...
    • The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). 

      Leach, MO; Eeles, RA; Turnbull, LW; Dixon, AK; Brown, J; Hoff, RJ; Coulthard, A; Dixon, JM; Easton, DF; Evans, DG; Gilbert, FJ; Hawnaur, J; Hayes, C; Kessar, P; Lakhani, S; Liney, G; Moss, SM; Padhani, AP; Pointon, LJ; Sydenham, M; Walker, LG; Warren, RM; Haites, NE; Morrison, P; Cole, T; Rayter, Z; Donaldson, A; Shere, M; Rankin, J; Goudie, D; Steel, CM; Davidson, R; Chu, C; Ellis, I; Mackay, J; Hodgson, SV; Homfray, T; Douglas, F; Quarrell, OW; Eccles, DM; Gilbert, FG; Crothers, G; Walker, CP; Jones, A; Slack, N; Britton, P; Sheppard, DG; Walsh, J; Whitehouse, G; Teh, W; Rankin, S; Boggis, C; Potterton, J; McLean, L; Gordon, PA; Rubin, C (2002-09)
      The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS) is in progress. The study design, accrual to date, and related research projects are described. Revised accrual rates ...
    • UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. 

      Barnes, A; Alonzi, R; Blackledge, M; Charles-Edwards, G; Collins, DJ; Cook, G; Coutts, G; Goh, V; Graves, M; Kelly, C; Koh, D-M; McCallum, H; Miquel, ME; O'Connor, J; Padhani, A; Pearson, R; Priest, A; Rockall, A; Stirling, J; Taylor, S; Tunariu, N; van der Meulen, J; Walls, D; Winfield, J; Punwani, S (2018-01)
      OBJECTIVE: Application of whole body diffusion-weighted MRI (WB-DWI) for oncology are rapidly increasing within both research and routine clinical domains. However, WB-DWI as a quantitative imaging biomarker (QIB) has ...
    • Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131I-NaI treatments of differentiated thyroid cancer. 

      Mínguez, P; Flux, G; Genollá, J; Delgado, A; Rodeño, E; Sjögreen Gleisner, K (2016-10)
      PURPOSE: To investigate the possible differences between SPECT/CT based whole-remnant and maximum-voxel dosimetry in patients receiving radio-iodine ablation treatment of differentiated thyroid cancer (DTC). METHODS: ...